BioVersys and Shionogi have joined forces in an exciting partnership aimed at advancing innovative treatments for infectious diseases. The collaboration focuses on the development of new ansamycin leads as part of BioVersys’ BV500 programme. This strategic alliance marks a significant step towards addressing unmet medical needs in the field of infectious diseases.
The BV500 programme, based on BioVersys’ Ansamycin Chemistry platform, has garnered attention for its potential to revolutionize treatment approaches. Research teams from Lille, France, and Basel, Switzerland, have been working tirelessly to identify lead candidates with broad-spectrum anti-non-tuberculous mycobacteria (NTM) activity.
Shionogi’s exclusive option to license these molecules for further clinical development underscores the company’s commitment to driving scientific innovation in the fight against infectious diseases. John Keller, Shionogi’s director of the board and senior vice-president of research and development supervisory unit, expressed enthusiasm about the collaboration:
“This partnership reflects our dedication to developing groundbreaking therapies for infectious diseases with significant unmet needs.”
If selected as clinical candidates, Shionogi may exercise its license option, potentially leading to substantial milestones for BioVersys. The agreement outlines that BioVersys could receive up to SFr479m in regulatory and sales milestones in addition to royalties from international sales.
The BV500 programme’s origins trace back to a SmartLab public-private partnership with the University of Lille. Support from CF AMR Syndicate and funding from the EU IHI-funded RespiriN programme have played pivotal roles in advancing ongoing BV500 development stages.
Dr. Nawaz Khan, head of research at BioVersys, expressed optimism about the project’s prospects:
“BV500 holds great promise as a best-in-class therapeutic for NTM infections.”
Dr. Khan highlighted how this collaboration would validate their work and accelerate project development while leveraging diverse expertise within the team.
The joint research teams are poised to deliver not only clinical candidates but also back-up molecules during their collaborative efforts. With Shionogi holding an exclusive option for licensing these molecules globally for further clinical development and commercialization, both companies are primed to make significant strides in combating infectious diseases.
In conclusion, the partnership between BioVersys and Shionogi signifies a shared commitment towards advancing healthcare through cutting-edge research and collaborative innovation. By combining their scientific knowledge and operational capabilities, these two industry leaders are paving the way for transformative breakthroughs in treating infectious diseases.
Leave feedback about this